



# PHARMACEUTICALS

THE FOREFRONT OF INNOVATION

---

The pharmaceutical industry is facing a period rich with opportunity and uncertainty as businesses are confronted by the need to generate growth in a mature, competitive market while faced with increasing pricing pressures and contracting margins.

Blockbuster patent expiries and the entry of biosimilar products has seen innovative pharmaceutical companies change direction, resulting in a blurring of traditional lines in the market. Coupled with unprecedented collaboration between global players, this is driving innovative approaches to commercialising IP and transformative asset-driven transactions.

Combining deep scientific and technical knowledge, we apply our commercial nous and experience to anticipate and deliver innovative, value-enhancing solutions.

We partner with our clients at every level of their businesses to help them achieve their goals: from strategic advice on "bet-the-company" transactions and disputes to merger control, regulatory investigations, commercial contracts and licensing.

Our intellectual property lawyers, the majority of whom have scientific or engineering backgrounds, understand that innovation is at the heart of the pharmaceutical industry. We help the world's leading pharmaceutical companies to use intellectual property to achieve commercial outcomes and competitive advantage, and have acted on some of the most complex transactions and disputes in the market.

Our integrated pharmaceuticals team spans our network of offices, and together with our preferred, trusted local law firms, work as one to provide commercial solutions—wherever you operate.

---

# RECENT EXPERIENCE

## **HOFFMANN LA-ROCHE AG AND ROCHE PRODUCTS LIMITED (ROCHE)**

Advising F. Hoffmann La-Roche AG and Roche Products Limited (Roche) in a significant High Court victory against Pfizer, in an action concerning Avastin®, Roche's blockbuster treatment for various forms of cancer. The action centred on whether a UK court should grant a form of negative declaratory relief known as an "Arrow declaration" in circumstances where our client had no relevant patent rights in the UK, and the claimant (Pfizer) intended to use the declarations and judgment solely for the purposes of influencing foreign courts.

## **MYLAN LABORATORIES**

Advising in its significant victory in a SIAC arbitration commenced by Phosphagenics in Singapore arising from licensing and research agreements, in which Phosphagenics claimed damages of over US\$ 300 million

## **AUROBINDO PHARMA**

Advising on its acquisition of Apotex's commercial operations across five European countries. The transaction includes a portfolio of over 200 prescription drugs and 88 OTC products and an additional pipeline of over 20 products

## **A GLOBAL INNOVATOR PHARMACEUTICALS COMPANY**

Advising in an ICC arbitration seated in Singapore. This concerned a dispute with another global pharmaceuticals company arising out of a co-promotion agreement. Following a two-week merits hearing, our client won a significant award.

---

## **ABBVIE**

Advising AbbVie on its proposed US\$55 billion takeover of Shire, a FTSE-100 pharmaceutical company

---

## **CLARIS LIFE SCIENCES LIMITED**

Acting for Claris Life Sciences Limited on the sale of its Global Generic Injectables Business to Baxter for US\$ 625 million

---

## **OUR PEOPLE**



**ALAN  
MONTGOMERY**  
PARTNER, LONDON

+44 20 7466 2618  
alan.montgomery@hsf.com



**SHAUN MCVICAR**  
PARTNER,  
MELBOURNE

+61 3 9288 1587  
Shaun.McVicar@hsf.com